Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million ...Middle East

AACHEN, Germany, Aug. 4, 2022 /PRNewswire/ -- Grünenthal and Shionogi announced today that they have entered into a licensing agreement for Grünenthal's investigational medicine Resiniferatoxin ("RTX"). Shionogi obtained the exclusive rights to commercialise Grünenthal's asset in Japan...

Hence then, the article about grunenthal to license osteoarthritis pain treatment to shionogi in japan in deal of up to 500 million was published today ( Thursday 04/08/2022 - 10:12 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million )

Also on site :

• Another Weight Loss Surgery and a Wedding Bombshell: Spoilers From '1000-Lb Sisters' Season 8 Episode 2
• Trump-Iran latest: President threatens ‘very strong action’ if protesters are hanged after forced confessions
• Saks Global Secures $1.75 Billion of Committed Capital and Announces Return of Industry Veterans to Advance Transformation of Iconic Luxury Portfolio